Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2025 | 2 | $0.02 | $0.03 | $0.03 |
Q2 2025 | 1 | $0.05 | $0.05 | $0.05 |
Q3 2025 | 1 | $0.05 | $0.05 | $0.05 |
Q4 2025 | 1 | $0.11 | $0.11 | $0.11 |
Q1 2026 | 1 | $0.02 | $0.02 | $0.02 |
Q2 2026 | 1 | $0.03 | $0.03 | $0.03 |
Q3 2026 | 1 | $0.05 | $0.05 | $0.05 |
Q4 2026 | 1 | $0.10 | $0.10 | $0.10 |
Cytek Biosciences, Inc. last posted its earnings results on Tuesday, November 5th, 2024. The company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of $0.00375 by $0.00625. The company had revenue of 51.50 M for the quarter and had revenue of 193.02 M for the year. Cytek Biosciences, Inc. has generated $0 earnings per share over the last year ($-0.0898 diluted earnings per share) and currently has a price-to-earnings ratio of -86.27. Cytek Biosciences, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/06/2024 | Q3 2024 | $0.01 | $50.70 M | $51.50 M | ||
08/06/2024 | Q2 2024 | -$0.03 | -$0.08 | -0.05 | $49.53 M | $46.62 M |
05/08/2024 | Q1 2024 | -$0.05 | -$0.05 | 0 | $44.86 M | |
03/13/2024 | Q4 2023 | $0.03 | $0.04 | 0.01 | $58.23 M | |
11/14/2023 | Q3 2023 | -$0.05 | $55.48 M | $48.00 M | ||
08/08/2023 | Q2 2023 | -$0.01 | -$0.03 | -0.02 | $45.71 M | $49.69 M |
05/09/2023 | Q1 2023 | -$0.02 | -$0.05 | -0.04 | $37.09 M | |
03/01/2023 | Q4 2022 | $0.00 | $48.34 M | |||
11/09/2022 | Q3 2022 | $0.02 | $0.01 | -0.01 | $43.29 M | $40.48 M |
08/10/2022 | Q2 2022 | $0.02 | -$0.00 | -0.02 | $39.63 M | $40.16 M |
05/11/2022 | Q1 2022 | -$0.02 | $35.06 M | |||
03/17/2022 | Q4 2021 | $0.00 | $38.89 M | |||
11/12/2021 | Q3 2021 | $0.01 | $33.37 M | $34.38 M | ||
09/02/2021 | Q2 2021 | $0.02 | $28.27 M | $30.41 M | ||
03/30/2021 | Q1 2021 | $0.00 | $24.27 M | |||
12/30/2020 | Q4 2020 | $0.05 | $30.62 M | |||
09/29/2020 | Q3 2020 | $0.21 | $25.10 M | |||
06/29/2020 | Q2 2020 | $0.26 | $19.14 M | |||
03/30/2020 | Q1 2020 | -$0.01 | $17.99 M |
Cytek Biosciences, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based off last year's report dates.
In the previous quarter, Cytek Biosciences, Inc. (:CTKB) reported $0.01 earnings per share (EPS) to beat the analysts' consensus estimate of $0.00375 by $0.00625.
The conference call for Cytek Biosciences, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Cytek Biosciences, Inc.'s latest earnings report can be read online.
Cytek Biosciences, Inc. (:CTKB) has a recorded annual revenue of $193.02 M.
Cytek Biosciences, Inc. (:CTKB) has a recorded net income of $193.02 M. Cytek Biosciences, Inc. has generated $-0.0898 earnings per share over the last four quarters.
Cytek Biosciences, Inc. (:CTKB) has a price-to-earnings ratio of -86.27 and price/earnings-to-growth ratio is -2.12.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED